To evaluate clinical factors affecting Gleason score upgrade in patients receiving radical prostatectomy (RP).
A total of 322 patients with prostate cancer who received RP from January 2012 to December 2013 at Department of Urology at Fudan University Shanghai Cancer Center were included, and their data of age, body mass index (BMI), prostate-specific antigen (PSA), prostate volume, percentage core, clinical staging, pathological characteristics, biopsy Gleason score and RP Gleason score were analyzed.
Differences in categorical variables and continuous variables were compared using χ(2) tests and Student's t-test, respectively. Unconditional multiple logistic regression was used to estimate OR and 95% CI of the association of Gleason score upgrade with clinical factors.
Gleason score upgrade occurred in 107 of 322 (33. 3%) patients. There was no difference in age, BMI and clinical staging between the two groups. Compared with patients without Gleason score upgrade, higher levels of PSA (χ(2)=6. 740, P=0. 034), smaller prostate volume (t=3. 481, P=0. 002) and elevated percentage core (t=-2. 097, P=0. 037) were observed in patients with Gleason score upgrade. In addition, lymph node metastasis (χ(2)=4. 193, P=0. 041) and extracapsular extension (χ(2)=4. 747, P=0. 029) were more common in patients with Gleason score upgrade. After adjusting for potential confounders, PSA levels (OR=2. 451, 95% CI: 1. 290-4. 660), prostate volume (OR=0. 982, 95% CI: 0. 969-0. 995) and percentage core (OR=2. 756, 95% CI: 1. 033-7. 357) were independent predictors for Gleason score upgrade.
Gleason score upgrade happens at a relatively high rate. PSA levels, prostate volume and percentage core are important factors affecting Gleason score upgrade.
Zhonghua wai ke za zhi [Chinese journal of surgery]. 2015 Jul [Epub]
Guiming Zhang, Xiaojian Qin, Chengtao Han, Chengyuan Gu, Fangning Wan, Yuanyuan Qu, Weijie Gu, Chunguang Ma, Yao Zhu, Dingwei Ye
Department of Urology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China. , Department of Urology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China. , Department of Urology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China. , Department of Urology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China. , Department of Urology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China. , Department of Urology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China. , Department of Urology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China. , Department of Urology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China. , Department of Urology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China. , Department of Urology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China